Jongkundang Bio, Launches Next-Generation Botulinum Toxin 'TMVus'

[Financial News] Jongkundang Bio announced on the 22nd that it has launched the next-generation botulinum toxin preparation 'TMVus'. TMVus is a product indicated for the treatment of moderate to severe frown lines and was developed based on a strain exclusively licensed from a European research institution. It is characterized by the use of non-animal excipients instead of human serum albumin (HSA), fundamentally blocking the risk of infection from blood-derived pathogens.
Jongkundang Bio secured the efficacy and safety of TMVus in a Phase 3 clinical trial conducted on 300 domestic patients with moderate to severe frown lines.
Through randomized, double-blind, active-controlled, multi-center clinical trials, it proved non-inferiority compared to Botox. It was confirmed that there was no difference in the incidence of adverse reactions between the treatment groups and no serious drug-related adverse reactions.
The study was recently published in the SCIE-level international journal 'Journal of Cosmetic Dermatology'.
In particular, by introducing a non-animal (vegan) process that thoroughly excludes animal-derived ingredients, it became the world's first botulinum toxin preparation to obtain halal certification from the Indonesian Halal Product Assurance Agency (BPJPH).
By developing it with a strain officially registered in the genome information database GenBank of the U.S. National Center for Biotechnology Information (NCBI), it secured a foundation for global market entry by blocking legal risks related to strain sources.
A representative from Jongkundang Bio said, “TMVus is a next-generation botulinum toxin preparation that has proven its safety and efficacy through systematic clinical trials based on strains with transparent sources,” adding, “Based on the world's first halal certification, we will expand into global markets, including Islamic countries such as Indonesia, the Middle East, and Malaysia.”

vrdw88@fnnews.com Kang Jungmo Reporter